Skip to main content

Table 2 Review of literature on anti-MOG antibodies in adult NMO/NMOSD

From: Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Publication MOG+ NMO (SD) (%AQP-seroneg.) Assay Characteristics of MOG+ NMOSD patients
Gender (%fem.) Clinical presentation/MRI Outcome (median f/u in months)
Mader [8] n = 10 CBA 70 n.a. n.a.
(39%)
Kezuka [9] n = 8 ELISA n.a. n.a. No improvement of visual acuity
(57%)
Kitley [10] n = 4 CBA 25 Monophasic simultaneous or sequential TM and ON; lower spinal cord involvement on MRI Excellent recovery (12)
(15%)
Sato [13] n = 16 CBA 38 More restricted phenotype (ON > TM); bilateral simultaneous ON; single attack; lower spinal cord involvement on MRI Good recovery in 88% (24)
(21%)
Kitley [12] n = 9 CBA 44 Simultaneous/sequential ON/TM; conus and deep gray nuclei involvement on MRI Better outcomes; less risk for disability (18)
(35%)
Höftberger [16] n = 16 CBA 53 Higher frequency of involvement of all spinal cord regions Better outcomes; less risk for disability (67)
(16%)
Ramanathan [14] n = 9 CBA 67 Strong association with BON; optic disk swelling Propensity to relapse (28)
(39%)
  1. Summary of the published literature on anti-MOG antibodies in adult NMO/NMOSD listed in PubMed until October 2014: The first two publications of the table summarize the literature not solely focused on NMO/NMOSD, while the other reports summarize the publications with a systematic analysis of anti-MOG antibodies in NMO/NMOSD. Abbreviations: BON, bilateral optic neuritis; CBA, cell-based assay; ELISA, enzyme-linked immunosorbent assay; fem., female; f/u, follow-up; MOG, myelin oligodendrocyte glycoprotein; n.a., not available; NMO, neuromyelitis optica; NMOSD, neuromyelitis optica spectrum disease; ON, optic neuritis; TM, transverse myelitis.